Core Viewpoint - The medical services sector experienced a rise of 1.19% on January 23, with notable gains from companies like Nuohua Zhiyuan, which led the sector's performance [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1]. - The medical services sector saw significant individual stock movements, with Nuohua Zhiyuan (688315) closing at 17.00, up 13.26%, and Hai Te Biological (300683) closing at 33.31, up 7.66% [1]. Group 2: Trading Volume and Value - Nuohua Zhiyuan had a trading volume of 219,500 shares and a transaction value of 365 million yuan [1]. - Hai Te Biological recorded a trading volume of 190,900 shares with a transaction value of 632 million yuan [1]. Group 3: Capital Flow - The medical services sector saw a net inflow of 999.1 million yuan from institutional investors, while retail investors experienced a net outflow of 1.069 billion yuan [2]. - The capital flow data indicates that major stocks like Diyan Diagnosis (300244) had a net inflow of 288 million yuan from institutional investors [3].

证券日报网讯1月15日，诺思格（301333）在互动平台回答投资者提问时表示，鉴于公司与客户普遍签 署保密协议，不便披露具体信息。 ...

Group 1 - The AI healthcare and AI pharmaceutical sectors experienced significant fluctuations, with notable declines in stock prices [1] - Hongbo Pharmaceutical saw a drop of over 18%, while Nossger fell nearly 15% [1] - Other companies such as International Medicine, Boji Pharmaceutical, Jiahe Meikang, and Berry Genomics also reported declines exceeding 5% [1]

Group 1 - The CRO index experienced a decline of 2.66% during intraday trading, with all constituent stocks showing a downward trend [1] - Hongbo Pharmaceutical led the decline with a drop of 19%, followed by Nossig at 9.65%, Yinos at 15%, Chengdu XianDao at 5%, and Boji Pharmaceutical at 4% [1]

证券代码：301333 证券简称：诺思格 公告编号：2026-003 诺思格（北京）医药科技股份有限公司 4、公司、控股股东和实际控制人不存在关于本公司的应披露而未披露的重 大事项，或处于筹划阶段的重大事项； 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的具体情况 诺思格（北京）医药科技股份有限公司（以下简称"公司"） 股票于 2026 年 1 月 13 日、2026 年 1 月 14 日连续两个交易日收盘价格涨幅偏离值累计超过 30%，根据《深圳证券交易所交易规则》的相关规定，属于股票交易异常波动的 情况。 二、说明关注、核实情况 针对公司股票交易异常波动情况，公司董事会对公司、控股股东及实际控制 人就相关事项进行了核实，现将有关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处； 2、公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生 较大影响的未公开重大信息； 3、近期公司经营情况及内外部经营环境未发生重大变化； 5、公司控股股东和实际控制人在股票交易异常波动期间未买卖公司股票。 三、 ...

证券之星消息，1月14日医疗服务板块较上一交易日上涨0.8%，诺思格领涨。当日上证指数报收于 4126.09，下跌0.31%。深证成指报收于14248.6，上涨0.56%。医疗服务板块个股涨跌见下表： 从资金流向上来看，当日医疗服务板块主力资金净流出24.65亿元，游资资金净流入4.18亿元，散户资金 净流入20.48亿元。医疗服务板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Group 1 - The core viewpoint of the article highlights that Norsg has achieved a consecutive two-day limit-up in trading, indicating strong market interest and performance [1] - The stock reached a trading limit at 10:16 AM with a transaction volume of 549 million yuan and a turnover rate of 11.75% [1] - The healthcare service sector has seen an overall rise, with Norsg being a clinical CRO company that offers comprehensive clinical trial services [1] Group 2 - Norsg has developed an AI platform that integrates clinical trial protocols and medical literature data, applicable in various clinical research scenarios [1] - The improvement in profit expectations following the implementation of innovative drug insurance negotiations and the shift of overseas orders to domestic markets are key factors driving the stock's performance [1] - The increasing market attention towards AI in healthcare is also contributing to the stock's upward momentum [1]

Group 1 - The healthcare services sector opened with a continuous upward trend, with Puris rising over 14% and reaching a new high during the session [1] - Meiyuan Health achieved a four-day consecutive increase, while New Mileage recorded a two-day consecutive increase [1] - International Medicine hit the daily limit, and companies such as Boteng Co., Zhaoyan New Drug, Nossger, Lanwei Medicine, and Berry Genomics also experienced gains [1]

Core Viewpoint - The healthcare sector has shown a strong upward trend in opening trading, with several companies experiencing significant gains and reaching new highs [1] Group 1: Company Performance - Puris has surged over 14% and reached an intraday high [1] - Meiyuan Health has achieved a four-day consecutive increase [1] - New Mileage has recorded a two-day consecutive increase [1] - International Medicine has hit the daily limit [1] - Boteng Co., Zhaoyan New Drug, Nossger, Lanwei Medical, and Berry Genomics have also seen upward movements [1]

Core Insights - The medical services sector experienced a significant increase of 4.15% on January 13, with Norska leading the gains [1] - The Shanghai Composite Index closed at 4138.76, down 0.64%, while the Shenzhen Component Index closed at 14169.4, down 1.37% [1] Group 1: Stock Performance - Norska (301333) closed at 76.48, up 20.01% with a trading volume of 55,200 shares and a transaction value of 397 million yuan [1] - Yingsi (301257) also saw a rise of 20.00%, closing at 72.24 with a trading volume of 22,900 shares [1] - Hongbo Pharmaceutical (301230) increased by 20.00%, closing at 56.64 with a trading volume of 57,200 shares [1] - Lanwei Medical (301060) rose by 19.96%, closing at 13.28 with a trading volume of 135,210 shares [1] - Boji Pharmaceutical (300404) increased by 19.96%, closing at 12.92 with a trading volume of 627,100 shares [1] - Dian Diagnostics (300244) saw an increase of 11.90%, closing at 29.16 with a trading volume of 1,516,000 shares [1] Group 2: Capital Flow - The medical services sector saw a net inflow of 1.497 billion yuan from institutional investors, while retail investors experienced a net outflow of 713 million yuan [2] - The main stocks with significant capital flow include International Medical (000516) with a net inflow of 259 million yuan from institutional investors [3] - Boji Pharmaceutical (300404) had a net inflow of 243 million yuan from institutional investors, but also saw a net outflow of 140 million yuan from retail investors [3]